Timing and patterns of recurrence in epithelial ovarian cancer patients with no gross residual disease after primary debulking surgery

被引:15
作者
Paik, E. Sun [1 ]
Lee, Yoo-Young [1 ]
Shim, Minhee [1 ]
Choi, Hyun Jin [1 ]
Kim, Tae-Joong [1 ]
Choi, Chel Hun [1 ]
Lee, Jeong-Won [1 ]
Kim, Byoung-Gie [1 ]
Bae, Duk-Soo [1 ]
机构
[1] Sungkyunkwan Univ, Sch Med, Dept Obstet & Gynecol, Samsung Med Ctr, 81 Irwon Ro, Seoul 135710, South Korea
关键词
neoplasms; ovarian neoplasms; prognosis; recurrence; residual; METASTATIC MUCINOUS ADENOCARCINOMAS; CHEMOTHERAPY; SURVIVAL; STATISTICS; PREDICTORS; RESECTION; RISK;
D O I
10.1111/ajo.12529
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
ObjectiveThe aim of this study was to analyse patterns and timing of recurrence and their association with clinical outcomes in recurrent epithelial ovarian cancer (EOC) patients with no gross residual disease after primary debulking surgery (PDS). MethodsThis study was conducted on 303 EOC patients with no residual disease after PDS who were treated at the Samsung Medical Center from 2002 to 2012. By reviewing electronic medical records, information on date of clinical/pathological recurrence and pattern of disease presentation for each relapse were retrieved. ResultsWithin a median follow-up of 53 months (range 3-156), 88 recurrences (29.0%) and 28 cancer-related deaths (9.2%) were observed. Most of the recurrences were distant, discrete and transcoelomic. After complete cytoreduction, the initial stage was associated with location of recurrence, but not with recurrence patterns. Complete cytoreduction reduced the number of recurrences, but it did not affect timing of recurrence. In multivariate analysis for overall survival (OS), patients with distant recurrence, diffuse carcinomatosis and mixed spread pattern of transcoelomic, lymphatic and haematogenous recurrence were found to have higher risk. ConclusionsWe found that timing of recurrence was not affected by complete cytoreduction. Location, type and pattern of recurrence were also significant prognostic factors for OS, in addition to known prognostic predictors such as platinum sensitivity.
引用
收藏
页码:639 / 647
页数:9
相关论文
共 50 条
[21]   Pattern of and reason for postoperative residual disease in patients with advanced ovarian cancer following upfront radical debulking surgery [J].
Heitz, Florian ;
Harter, Philipp ;
Alesina, Piero F. ;
Walz, Martin K. ;
Lorenz, Dietmar ;
Groeben, Harald ;
Heikaus, Sebastian ;
Fisseler-Eckhoff, Anette ;
Schneider, Stephanie ;
Ataseven, Beyhan ;
Kurzeder, Christian ;
Prader, Sonia ;
Beutel, Bianca ;
Traut, Alexander ;
du Bois, Andreas .
GYNECOLOGIC ONCOLOGY, 2016, 141 (02) :264-270
[22]   Impact of the Time Interval Between Primary Debulking Surgery and Start of Adjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer [J].
Lin, Hao ;
Chen, Wen-Hsin ;
Wu, Chen-Hsuan ;
Ou, Yu-Che ;
Chen, Yu-Jen ;
Chen, Ying-Yi ;
Lin, Yu-Han ;
Fu, Hung-Chun .
CANCER MANAGEMENT AND RESEARCH, 2021, 13 :5413-5422
[23]   Case report: Minimally invasive primary debulking surgery for advanced stage epithelial ovarian cancer [J].
Wolf, Jennifer ;
Goncalves, Nicole ;
Alagkiozidis, Ioannis .
FRONTIERS IN ONCOLOGY, 2024, 14
[24]   Primary debulking surgery or neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer [J].
Hong Zheng ;
Yu-Nong Gao .
ChineseJournalofCancerResearch, 2012, 24 (04) :304-309
[25]   Primary debulking surgery or neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer [J].
Zheng, Hong ;
Gao, Yu-Nong .
CHINESE JOURNAL OF CANCER RESEARCH, 2012, 24 (04) :304-309
[26]   Secondary cytoreductive surgery in patients presenting with isolated nodal recurrence of epithelial ovarian cancer [J].
Fotiou, Stelios ;
Aliki, Tserkezoglou ;
Petros, Zarganis ;
Ioanna, Stauropoulou ;
Konstantinos, Velentzas ;
Vasiliki, Michalaki ;
George, Creatsas .
GYNECOLOGIC ONCOLOGY, 2009, 114 (02) :178-182
[27]   Interval debulking surgery in advanced epithelial ovarian cancer [J].
Pecorelli, S ;
Odicino, F ;
Favalli, G .
BEST PRACTICE & RESEARCH IN CLINICAL OBSTETRICS & GYNAECOLOGY, 2002, 16 (04) :573-583
[28]   Prognostic impact of microscopic residual disease after neoadjuvant chemotherapy in patients undergoing interval debulking surgery for advanced ovarian cancer [J].
Di Donato, Violante ;
Caruso, Giuseppe ;
Golia D'Auge, Tullio ;
Perniola, Giorgia ;
Palaia, Innocenza ;
Tomao, Federica ;
Muzii, Ludovico ;
Pernazza, Angelina ;
Della Rocca, Carlo ;
Bogani, Giorgio ;
Panici, Pierluigi Benedetti ;
Giannini, Andrea .
ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2025, 311 (02) :429-436
[29]   Using an evidence-based triage algorithm to reduce 90-day mortality after primary debulking surgery for advanced epithelial ovarian cancer [J].
Narasimhulu, Deepa M. ;
Kumar, Amanika ;
Weaver, Amy L. ;
McGree, Michaela E. ;
Langstraat, Carrie L. ;
Cliby, William A. .
GYNECOLOGIC ONCOLOGY, 2019, 155 (01) :58-62
[30]   Timing of interval debulking surgery and postoperative chemotherapy after neoadjuvant chemotherapy in advanced epithelial ovarian cancer: a multicenter real-world study [J].
Liu, Xingyu ;
Zhao, Yingjun ;
Jiao, Xiaofei ;
Yu, Yang ;
Li, Ruyuan ;
Zeng, Shaoqing ;
Chi, Jianhua ;
Ma, Guanchen ;
Huo, Yabing ;
Li, Ming ;
Peng, Zikun ;
Liu, Jiahao ;
Zhou, Qi ;
Zou, Dongling ;
Wang, Li ;
Li, Qingshui ;
Wang, Jing ;
Yao, Shuzhong ;
Chen, Youguo ;
Ma, Ding ;
Hu, Ting ;
Gao, Qinglei .
JOURNAL OF OVARIAN RESEARCH, 2023, 16 (01)